Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity

Journal article


Publication Details

Author(s): Hahn F, Hutterer C, Henry C, Hamilton ST, Strojan H, Kraut A, Schulte U, Schuetz M, Kohrt S, Wangen C, Pfizer J, Coute Y, Rawlinson WD, Strobl S, Marschall M
Journal: Antiviral Research
Publication year: 2018
Volume: 159
Pages range: 84-94
ISSN: 0166-3542


Abstract

Human cytomegalovirus (HCMV) is a major human pathogen with seropositivity rates in the adult population ranging between 40% and 95%. HCMV infection is associated with severe pathology, such as life-threatening courses of infection in immunocompromised individuals and neonates. Current standard therapy with valganciclovir has the disadvantage of adverse side effects and viral drug resistance. A novel anti-HCMV drug, letermovir, has been approved recently, so that improved therapy options are available. Nevertheless, even more so far unexploited classes of compounds and molecular modes of action will be required for a next generation of antiherpesviral treatment strategies. In this study, we focused on the analysis of the antiviral potency of a novel class of compounds, i.e. pyrrolopyridine analogs, and identified both hit compounds and their target protein candidates. In essence, we provide novel evidence as follows: (i) screening hit SC88941 is highly active in inhibiting HCMV replication in primary human fibroblasts with an EC50 value of 0.20 +/- 0.01 mu M in the absence of cytotoxicity, (ii) inhibition occurs at the early-late stage of viral protein production and shows reinforcing effects upon LMV cotreatment, (iii) among the viruses analyzed, antiviral activity was most pronounced against beta-herpesviruses (HCMV, HHV-6A) and intermediate against adenovirus (HAdV-2), (iv) induction of SC88941 resistance was not detectable, thus differed from the induction of ganciclovir resistance, (v) a linker-coupled model compound was used for mass spectrometry-based target identification, thus yielding several drug-binding target proteins and (vi) a first confocal imaging approach used for addressing intracellular effects of SC88941 indicated qualitative and quantitative alteration of viral protein expression and localization. Thus, our findings suggest a multifaceted pattern of compound-target binding in connection with an unusual mode of action, opening up further opportunities of antiviral drug development.


FAU Authors / FAU Editors

Hahn, Friedrich
Professur für Virologie
Kohrt, Stephan
Professur für Mikrobiologie


External institutions with authors

4SC AG
University of Grenoble Alpes (UGA) / Université de Grenoble
University of New South Wales (UNSW)


How to cite

APA:
Hahn, F., Hutterer, C., Henry, C., Hamilton, S.T., Strojan, H., Kraut, A.,... Marschall, M. (2018). Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity. Antiviral Research, 159, 84-94. https://dx.doi.org/10.1016/j.antiviral.2018.09.012

MLA:
Hahn, Friedrich, et al. "Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity." Antiviral Research 159 (2018): 84-94.

BibTeX: 

Last updated on 2019-07-02 at 09:23